Drugs / RO5458640
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01383733 | Jul 2011 → Mar 2013 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5458640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01383733 ↗ |
| Known as | RG-7212 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109600 ↗ |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 12 inhibitor” CHEMBL2109600 ↗ |
| Route | Intravenous | “receive ascending doses of RO5458640 intravenously” NCT01383733 ↗ |
| Target | TNFSF12 | “Tumor necrosis factor ligand superfamily member 12 inhibitor” CHEMBL2109600 ↗ |